Fact Source: Financial Supervisory Service DART / 2026-06-17
Disclosure Type: Manufacturing Agreement (Amendment)
💡 3-Second Summary
Samsung Biologics has amended its contract manufacturing agreement signed on April 28, 2025, with a U.S.-based pharmaceutical company, increasing the total contract value from KRW 737.3B to KRW 835.6B upon the client’s request.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Reason for Amendment: Modification of contract value as requested by the client.
- Contract Details (Contract Manufacturing Agreement):
- Contract Value: (Pre-amendment) KRW 737,326,729,080 ➔ (Post-amendment) KRW 835,687,639,260 (Increased by KRW 98,360,910,180)
- Ratio to Sales: (Pre-amendment) 16.21% ➔ (Post-amendment) 18.38% (Compared to the FY2024 consolidated sales of KRW 4,547,322,176,421)
- Value in USD: Increased by USD 68,563,300 from the previous USD 513,959,800, bringing the new fixed total to USD 582,523,100 (Applying the initial FX rate of 1,434.60 KRW/USD as of April 28, 2025).
- Contract Term & Confidentiality Period: 2025-04-28 – 2031-12-31 (No changes)
- Counterparty: A pharmaceutical company located in the United States (Identity undisclosed until December 31, 2031, due to business confidentiality).
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This regulatory filing details modifications to the scale of an existing corporate supply agreement. The contract manufacturing organization (CMO) agreement, originally established in April 2025 with a U.S. pharmaceutical firm, has been revised upward by USD 68.56M (approximately KRW 98.3B) following a client request. The disclosure does not specify the explicit operational or internal drivers behind this pricing adjustment.
From a financial viewpoint, the ratio against baseline sales adjusted from 16.21% to 18.38%, indicating a potential expansion in the overall revenue recognition scale. However, market participants should be aware that both the contract value and the final expiration date (December 31, 2031) remain subject to further modifications depending on bilateral agreements. Furthermore, as the counterparty’s identity remains masked until 2031 under confidentiality clauses, analyzing partner-specific risks directly from this filing is limited.
📝 Editor’s Comment (by K-STOCK Editor)
A large-scale supply contract initiated in April 2025 has been re-adjusted after approximately one year, resulting in an increased contract value upon the counterparty’s request. The total finalized value is now fixed at KRW 835.6B, representing 18.38% of the company’s FY2024 consolidated revenue. Because the filing attributes the amendment strictly to a “client request” without details on production volume changes or specific manufacturing terms, the structural reasons remain unstated. Given the long-term execution timeline extending through 2031, investors may focus on tracking potential future revisions and implementation status.
📢 Disclaimer & Source Information
Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service electronic disclosure system (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
